Section Arrow
ELEV.NASDAQ
- Elevation Oncology
(Financial Status)
Quotes are at least 15-min delayed:2025/07/21 06:43 EDT
Pre Market
Last
 0.3728
-0.0022 (-0.59%)
Bid
0.3727
Ask
0.3797
High 0.373 
Low 0.371 
Volume 2655 
Regular Hours
Last
 0.375
-0.0002 (-0.05%)
Day High 
0.375 
Prev. Close
0.3752 
1-M High
0.39 
Volume 
1.17M 
Bid
0.3727
Ask
0.3797
Day Low
0.3712 
Open
0.3725 
1-M Low
0.3616 
Market Cap 
22.23M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.38 
20-SMA 0.38 
50-SMA 0.35 
52-W High 3.09 
52-W Low 0.221 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.81/-0.57
Enterprise Value
53.37M
Balance Sheet
Book Value Per Share
0.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.13 -0.945 -6.71%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0475 -0.0002 -0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed:2025/07/21 06:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.